+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Multi-institutional evaluation of Depo-Provera for the treatment of hot flashes associated with androgen ablation for prostate cancer



Multi-institutional evaluation of Depo-Provera for the treatment of hot flashes associated with androgen ablation for prostate cancer



Journal of Urology 171(4 Suppl.): 384




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 035349249

Download citation: RISBibTeXText


Related references

Depo-provera as a treatment for hot flashes in men on androgen ablation therapy. Journal of Urology 153(4 Suppl. ): 448A, 1995

Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. Journal of Urology 162(1): 98, 1999

Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate. Journal of Urology 166(2): 517-520, 2001

Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. European Urology 74(1): 99, 2018

Depo-provera therapy for hot flushes associated with hormonal treatment of advanced carcinoma of the prostate. Journal of Urology 159(5 Suppl. ): 132, 1998

Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community-based multi-institutional database across Japan using propensity score matching. Cancer Medicine 7(10): 4893-4902, 2018

Depo provera treatment for sex offending behavior: an evaluation of outcome. Bulletin of the American Academy of Psychiatry and the Law 20(3): 249-259, 1992

Apoptosis and other mechanisms in androgen ablation treatment and androgen independent progression of prostate cancer: a review. Cancer Detection and Prevention 22(5): 476-484, 1998

Evaluation of the efficacy and safety of Salvia officinalis in controlling hot flashes in prostate cancer patients treated with androgen deprivation. PhytoTherapy Research 26(2): 208-213, 2012

Molecular analysis of the androgen receptor in prostate cancer specimens obtained before and after hormonal treatment Androgen ablation selects an androgen receptor with an expanded poly-glutamine repeat. Proceedings of the American Association for Cancer Research Annual Meeting (41): 238, 2000

Five-year retrospective, multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. Urology 57(3): 518-523, 2001

Response of estrogen and progesterone receptors to treatment with large doses of progestogen (depo-provera) in endometrial cancer. Zentralblatt für Gynakologie 112(17): 1111-1115, 1990

Reaction of estrogen and progesterone receptors in endometrial cancer to treatment with large doses of progestogen depo provera. Zentralblatt fuer Gynaekologie 112(17): 1111-1115, 1990

Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study. International Journal of Radiation Oncology Biology Physics 86(3): 540-545, 2013

Depo-provera: clinical evaluation. Contraceptive Delivery Systems 2(3): 259-269, 1981